Revvity, Inc. (RVTY) Stock

Revvity, Inc. (RVTY) is a Technology stock trading at $124.15 (as of 2026-08-20), with a market capitalization of $13.85B and a trailing P/E of 77.0. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Revvity, Inc. develops products and services for diagnostics and life sciences, including instruments, reagents, assay platforms, and related software and informatics for research, analytical testing, and early detection of genetic and infectious disease. It operates through Discovery & Analytical Solutions and Diagnostics segments, serving customers worldwide across laboratory, research, and applied analysis markets.

Understand Revvity, Inc.: how it makes money

Revvity sells tools and services for diagnostics, life sciences research, and applied services, including instruments, reagents, informatics and software, plus contract research and laboratory services, generating revenue from customer purchases and recurring software-related business.

Profit durability is likely anchored by Signals Software, since it represents 35% of the overall business and has 110% Signals Software Net Retention Rate with 40% Signals Software Annual Recurring Revenue as a Percentage.

Revenue by segment (latest quarter)
Discovery & Analytical Solutions$0.3B
Diagnostics$0.3B

Business quality (Mixed): The business mix appears to combine cyclical instrument and service demand with a recurring software component (Signals Software), where net retention is reported at 110% and recurring software is a large share of the overall business.

Valuation: At 54× earnings, RVTY trades 9% below the Measuring & Control Equipment average (60×). Note: one-time items can distort reported P/E.

Bull case

  • Recurring software stickiness: Signals Software shows 110% net retention.
  • Software is a meaningful part of revenue: Signals Software Share of Overall Business is 35%, and Signals Software Annual Recurring Revenue as a Percentage is 40%.

Bear case

  • End market dependence: Demand depends on customers in diagnostics and life sciences research, including the purchase of instruments and reagents and use of contract research and laboratory services.
  • Execution risk around recurring growth: The software-led model highlighted by retention and recurring mix could be pressured if Signals Software growth drivers weaken (for example, if retention or recurring mix changes).
Valuation — source: SEC EDGAR (first-party)
Price$124.15
Market Cap$13.85B
P/E Ratio77.0
EV / EBITDA28.2
Price / Book1.92
Price / Sales4.86
FCF Yield5.9%
DCF Value (model)$48.35
DCF Upside vs Price-61.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.86B
Net Margin8.4%
Revenue Growth (YoY)3.7%
EPS Growth (YoY)-6.3%
FCF Growth (YoY)-6.0%
Financial Health — source: SEC EDGAR
Altman Z-Score2.81 (grey)
Valuation vs Sector & Industry
Stock P/E77.0
Sector P/E (Technology)33.9
Industry P/E (Measuring & Control Equipment)51.8
vs Sector126.9%
vs Industry48.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderT. Rowe Price Investment Management, Inc. ($1.94B)
Institutional Holders Tracked10
Congressional Trades (recent)10
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEOPrahlad R. Singh
Employees11,000
CountryUS
IPO Date1965-07-06

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Agilent Technologies, Inc. (A)
  • Waters Corporation (WAT)
  • Illumina, Inc. (ILMN)
  • Mettler-Toledo International Inc. (MTD)
  • Bio-Rad Laboratories, Inc. (BIO)
  • Avantor, Inc. (AVTR)
  • Bruker Corporation (BRKR)
  • 10x Genomics, Inc. (TXG)
RVTY earnings history · RVTY institutional & insider holders · RVTY KPIs & operating metrics · RVTY financials · RVTY investor presentations & press releases · RVTY SEC filings · RVTY peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.